 | |
| Clinical data | |
|---|---|
| Pronunciation | /tɪpˈrænəvɪər/ tip-RAN-ə-veer |
| Trade names | Aptivus |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a606009 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth (softcapsules) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 99.9% |
| Metabolism | Liver |
| Eliminationhalf-life | 4.8–6 hours |
| Excretion | Feces (82.3%), urine (4.4%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| NIAID ChemDB | |
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.158.066 |
| Chemical and physical data | |
| Formula | C31H33F3N2O5S |
| Molar mass | 602.67 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Tipranavir (TPV), ortipranavir disodium, is a nonpeptidicprotease inhibitor (PI) manufactured byBoehringer Ingelheim under the trade nameAptivus/ˈæptəvəs/AP-tiv-əs. It is administered withritonavir incombination therapy to treatHIV infection.[citation needed]
Tipranavir has the ability to inhibit the replication ofviruses that are resistant to other protease inhibitors and is recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.[2] Tipranavir was approved by theFood and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.[3]
Tipranavir should only be taken in combination withritonavir and other antiretroviral drugs, and is not approved for treatment-naïve patients.[1] Likelopinavir andatazanavir, it is very potent and is effective insalvage therapy for patients with drug resistance. However, side effects of tipranavir may be more severe than those of other antiretrovirals. Some side effects includeintracranial hemorrhage,hepatitis,hepatic decompensation,hyperglycemia anddiabetes mellitus. The drug has also been shown to cause increases in totalcholesterol andtriglycerides.[1]
Aptivus labeling has ablack box warning regardinghepatotoxicity and intracranial hemorrhage.[1]
